Five‐ versus seven‐day dosing intervals of extended‐release injectable omeprazole in the treatment of equine squamous and glandular gastric disease

• Published in: Equine veterinary journal 2024-01, Vol.56 (1), p.51-58
• Main Authors: Sundra, Tania, Kelty, Erin, Rendle, David
• Format: Article
• Language: English
• Subjects: acid suppression; gastric ulcer; horse; Horses; proton pump inhibitor; therapeutics
• ISSN: 0425-1644; 2042-3306
• DOI: 10.1111/evj.13938

Background An extended‐release injectable omeprazole formulation (ERIO) has become a popular treatment for equine squamous gastric disease (ESGD) and equine glandular gastric disease (EGGD) where it is available; however, published data are limited and optimal treatment regimens have not been determined. Objectives To compare effects of treatment on ESGD and EGGD when an ERIO formulation is administered at either 5‐ or 7‐day intervals. Study design Retrospective clinical study. Methods Case records and gastroscopy images of horses with ESGD or EGGD treated with ERIO were reviewed. Images were anonymised and graded by one researcher masked to treatment group. Treatment responses were compared between the two treatment schedules using univariable ordered logistic regression. Results Forty‐three horses were treated with ERIO at 5‐day intervals and 39 horses at 7‐day intervals. Signalment and presenting signs did not differ between groups. The proportions of horses with EGGD healing (to grade 0 or 1) in association with ERIO used at 5‐day intervals (93%) were higher than associated with treatment at 7‐day intervals (69%; odds ratio [OR]: 2.41, 95% CI: 1.23–4.74, p = 0.01). For ESGD, there was no significant difference in the proportion of horses healing in association with treatment at 5‐day intervals (97%) compared with 7‐day intervals (82%; OR: 2.75, 95% CI: 0.91–8.31, p = 0.07). Four of 328 injections were associated with an injection‐site reaction (1%). Main limitations Retrospective study design, lack of randomisation and limited case numbers. Conclusions The use of ERIO at 5‐day intervals might be more appropriate than the 7‐day interval that is used currently. Zusammenfassung Hintergrund Eine injizierbare Omeprazolformulierung mit verlängerter Wirkstofffreisetzung (ERIO) hat sich zu einer beliebten Behandlungsmethode für die Equine Squamous Gastric Disease (ESGD) und die Equine Glandular Gastric Disease (EGGD) bei Pferden entwickelt, wo sie verfügbar ist. Die veröffentlichten Daten sind jedoch begrenzt und optimalen Behandlungsschemata wurden nicht ermittelt. Ziele Vergleich der Auswirkungen der Behandlung auf ESGD und EGGD, wenn eine ERIO‐Formulierung entweder in Abständen von fünf oder sieben Tagen verabreicht wird. Studiendesign Retrospektive klinische Studie. Methoden Fallberichte und Gastroskopiebilder von Pferden mit ESGD oder EGGD, die mit ERIO behandelt wurden, wurden überprüft. Die Bilder wurden anonymisiert und von einem der Autoren blind bewe